News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A.T.S. Pharmaceuticals, A Division of Auriga Laboratories, Inc. (ARGA.OB) Launches Xyralid(TM) RC


7/9/2007 12:36:18 PM

LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, announced today the launch of Xyralid™ RC (lidocaine HCL 3%/hydrocortisone acetate 1%) rectal cream kit, a convenience kit that contains a seven- day supply (14 units) of Xyralid Rectal Cream and a 7 day supply of Konsyl® Natural Bulk-Forming Laxative with a convenient shaker cup. Xyralid RC will be promoted to Gastroenterologists and Colon Rectal Specialists by the recently announced 46-person ATS Pharmaceutical division of Auriga. According to Wolters Kluwer Health, Inc., the overall US hemorrhoid prescription market exceeds $88 million annually. The American Society of Colon & Rectal Surgeons (ASCRS) recommends increasing the amount of fiber and fluids in the diet to relieve mild hemorrhoid symptoms1.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES